Home › Research › Treatments
Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial
Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG, ADAPT Research Team.. International journal of geriatric psychiatry, 2011-05-10
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective We examined the effects of non-steroidal anti-inflammatory drugs on cognitive decline as a function of phase of pre-clinical Alzheimer disease. Methods Given recent findings that cognitive decline accelerates as clinical diagnosis is approached, we used rate of decline as a proxy for phase of pre-clinical Alzheimer disease. We fit growth mixture models of Modified Mini-Mental State (3MS) Examination trajectories with data from 2388 participants in the Alzheimer's Disease Anti-inflammatory Prevention Trial and included class-specific effects of naproxen and celecoxib. Results We identified three classes: "no decline", "slow decline", and "fast decline", and examined the effects of celecoxib and naproxen on linear slope and rate of change by class. Inclusion of quadratic terms improved fit of the model (-2 log likelihood difference: 369.23; p Conclusions Our results appeared statistically robust but provided some unexpected contrasts in effects of different treatments at different times. Naproxen may attenuate cognitive decline in slow decliners while accelerating decline in fast decliners. Celecoxib appeared to have similar effects at first but then attenuated change in fast decliners.
What this study adds
Evidence grade: Low
This is a trial of 2,388 participants. This re-analysis of 2,388 participants in the Alzheimer's Disease Anti-inflammatory Prevention Trial used how fast people's 3MS cognitive test scores fell as a stand-in for how far pre-clinical Alzheimer's had progressed, and found three groups: no, slow and fast decline.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Leoutsakos, J. M., Muthen, B. O., Breitner, J. C., Lyketsos, C. G., & ADAPT Research Team. (2012). Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. International journal of geriatric psychiatry. https://doi.org/10.1002/gps.2723
Vancouver
Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG, ADAPT Research Team. Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. International journal of geriatric psychiatry. 2012. doi:10.1002/gps.2723. PMID: 21560159.
BibTeX
@article{leoutsakos2012-21560159,
author = {Leoutsakos, J. M. and Muthen, B. O. and Breitner, J. C. and Lyketsos, C. G. and {ADAPT Research Team}},
title = {{Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial}},
journal = {International journal of geriatric psychiatry},
year = {2012},
doi = {10.1002/gps.2723},
pmid = {21560159},
url = {https://doi.org/10.1002/gps.2723}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results We identified three classes: "no decline", "slow decline", and "fast decline", and examined the effects of celecoxib and naproxen on linear slope and rate of change by class.
- Inclusion of quadratic terms improved fit of the model (-2 log likelihood difference: 369.23; p Conclusions Our results appeared statistically robust but provided some unexpected contrasts in effects of different treatments at different times.
Why it matters
This re-analysis of 2,388 participants in the Alzheimer's Disease Anti-inflammatory Prevention Trial used how fast people's 3MS cognitive test scores fell as a stand-in for how far pre-clinical Alzheimer's had progressed, and found three groups: no, slow and fast decline. The authors report that naproxen "may attenuate cognitive decline in slow decliners while accelerating decline in fast decliners," while celecoxib "appeared to have similar effects at first but then attenuated change in fast decliners." They call these contrasts "unexpected," so the study suggests that drug effects may differ by disease phase; it does not show that anti-inflammatory drugs protect against Alzheimer's.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants2,388
- Evidence strengthLow
How this study scored 63/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (International journal of geriatric psychiatry) |
| Journal's citation record | 2 / 4 | International Journal of Geriatric Psychiatry: journal h-index 190 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2012 — within 20 year(s) of the newest study here |
| Sample size | 3 / 4 | 2,388 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 5 / 7 | Cited 104 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 6.5 citations a year over 16 year(s) since 2012 |
| Impact for its field and year | 3 / 6 | Cited 6.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 7 other studies in this library |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Constantine George Lyketsos: h-index 130 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | University of Washington: institution h-index 3,540 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 21560159) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 63 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.
Later studies that cite this one
7 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.